Compass Therapeutics Inc Stock Price, News & Analysis

Compass Therapeutics (NASDAQ: CMPX) announced significant results from its Phase 2/3 COMPANION-002 trial evaluating tovecimig in combination with paclitaxel for biliary tract cancer (BTC). The study met its primary endpoint, demonstrating a 17.1% overall response rate (ORR) for the combination therapy compared to 5.3% for paclitaxel alone (p=0.031).

The trial enrolled 168 patients with advanced BTC in the second-line setting, randomized 2:1 to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). Notable findings include one complete response in the combination arm and lower progressive disease rates (16.2% vs 42.1%). Secondary endpoints, including progression-free survival and overall survival, are expected to be reported in Q4 2025.

This development is particularly significant as approximately 23,000 BTC patients are diagnosed annually in the US, with 85% lacking approved second-line treatment options.

Compass Therapeutics (Nasdaq: CMPX) has announced a webcast scheduled for April 1, 2025, at 8:00 AM ET to present top-line clinical data from their ongoing Phase 2/3 COMPANION-002 trial. The study evaluates tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel for treating patients with advanced biliary tract cancer (BTC).

The virtual event will be accessible via webcast, with a replay available for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX) reported its 2024 financial results and provided key pipeline updates. The company's lead candidate tovecimig is on track for Phase 2/3 top-line data readout in biliary tract cancer by Q1 2025. The company ended 2024 with $127 million in cash, providing runway into Q1 2027.

Financial highlights include a net loss of $49.4 million ($0.36 per share) compared to $42.5 million in 2023. R&D expenses increased 11% to $42.3 million, while G&A expenses rose 24% to $15.1 million.

Pipeline progress includes:

• Advancement of CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards IND filing by end-2025
• Full enrollment of third dosing cohort for CTX-8371 Phase 1 study
• Planned initiation of two Phase 2 trials in mid-2025 for tovecimig and CTX-471
• 5% ORR achieved for tovecimig in colorectal cancer patients

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.

The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.

Compass Therapeutics (NASDAQ: CMPX) provided a corporate update highlighting key developments in its oncology pipeline. The company's lead candidate tovecimig (CTX-009) is on track for Phase 2/3 top-line data in biliary tract cancer by Q1 2025. A new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, is advancing with IND submission expected by end of 2025.

Two Phase 2 biomarker trials are planned for mid-2025: tovecimig in DLL4-positive colorectal cancer and CTX-471 in NCAM/CD56 expressing tumors. The Phase 1 dose-escalation study of CTX-8371 has fully enrolled its third cohort, with preliminary data expected in H2 2025.

The company reports an estimated $127 million in cash and marketable securities at YE 2024, providing runway into Q1 2027.

Compass Therapeutics (CMPX) has appointed Barry Shin as Chief Financial Officer effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical leadership, including finance, operations, investment banking, and corporate advisory roles. Most recently, he served as EVP, COO & CFO at Trevena, Inc.

The appointment comes at a important time for Compass, with several key catalysts expected in 2025, including topline data readout for CTX-009 in the first quarter. CEO Thomas Schuetz highlighted Shin's expertise in financial planning, capital markets, and M&A as valuable assets for advancing CTX-009 and the company's portfolio of clinical and pre-clinical assets.

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. The company's presentation is scheduled for Wednesday, December 4, 2024, from 9:50-10:10 AM EST. A webcast of the presentation will be available and archived for 90 days on Compass' Events page.

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 PM ET, and at the Jefferies London Healthcare Conference in London on November 21 at 2:00 PM GMT. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX) reported Q3 2024 financial results and corporate updates. The company fully enrolled its Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected by Q1 2025. Net loss was $10.5 million ($0.08 per share) for Q3 2024. The company maintains a strong financial position with $135 million in cash and marketable securities, providing runway into Q1 2027. R&D expenses were $8.6 million, while G&A expenses increased to $3.6 million. Key pipeline developments include progress in CTX-471 trials with NCAM identified as a potential response biomarker, and advancement in CTX-8371's Phase 1 dose-escalation study.